| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Sign In to gain access to subscriptions and/or personal tools.
|
|
|
|||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
Articles |
Thirty-seven young and elderly male and female volunteers 21 to 76 years of age received a single 25-mg oral dose of diphenhydramine or matching placebo in a double-blind, randomized, two-way crossover study. Plasma diphenhydramine concentrations, self-ratings of sedation, mood, and autonomic effects, performance on the digit-symbol substitution test (DSST), and heart rate were determined for 24 hours after administration. Information acquisition and recall were tested at 2.5 and 24 hours after administration. Age and gender did not significantly influence diphenhydramine peak plasma concentration, time of peak concentration, elimination half-life, area under the plasma concentration curve, or apparent oral clearance. Effects on psychomotor performance, sedation, mood, and memory did not differ between diphenhydramine and placebo in either group. Thus, the pharmacokinetics of single 25-mg oral doses of diphenhydramine are not influenced by age or gender. This dose of diphenhydramine produces essentially undetectable pharmacodynamic effects in both the young and elderly.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  D. J. Greenblatt, J. S. Harmatz, and A. Karim Age and Gender Effects on the Pharmacokinetics and Pharmacodynamics of Ramelteon, a Hypnotic Agent Acting via Melatonin Receptors MT1 and MT2 J. Clin. Pharmacol., April 1, 2007; 47(4): 485 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Frick, M. Roos, and K. Fattinger How much is too much? Oligosymptomatic presentation after 11.5 g of diphenhydramine Human and Experimental Toxicology, February 1, 2007; 26(2): 131 - 133. [Abstract] [PDF]
|
|
|
|
|
|
D. J. Greenblatt, E. Legangneux, J. S. Harmatz, E. Weinling, J. Freeman, K. Rice, and G. K. Zammit Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. J. Clin. Pharmacol., December 1, 2006; 46(12): 1469 - 1480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Greenblatt, L. L. von Moltke, J. S. Harmatz, S. M. Fogelman, G. Chen, J. A. Graf, P. Mertzanis, S. Byron, K. E. Culm, B. W. Granda, et al. Short-Term Exposure to Low-Dose Ritonavir Impairs Clearance and Enhances Adverse Effects of Trazodone J. Clin. Pharmacol., April 1, 2003; 43(4): 414 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. H. Lee, J. Dudley, and H. J. Demonaco Drug Effects on Driving Performance Ann Intern Med, October 17, 2000; 133(8): 656 - 657. [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Greenblatt, J. S. Harmatz, L. L. von Moltke, C. E. Wright, A. L. B. Durol, L. M. Harrel-Joseph, and R. I. Shader Comparative Kinetics and Response to the Benzodiazepine Agonists Triazolam and Zolpidem: Evaluation of Sex-Dependent Differences J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 435 - 443. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
